These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 26953185)

  • 1. Evaluation of Rifampin's Transporter Inhibitory and CYP3A Inductive Effects on the Pharmacokinetics of Venetoclax, a BCL-2 Inhibitor: Results of a Single- and Multiple-Dose Study.
    Agarwal SK; Hu B; Chien D; Wong SL; Salem AH
    J Clin Pharmacol; 2016 Nov; 56(11):1335-1343. PubMed ID: 26953185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics.
    Freise KJ; Hu B; Salem AH
    Eur J Clin Pharmacol; 2018 Apr; 74(4):413-421. PubMed ID: 29302721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model.
    Freise KJ; Shebley M; Salem AH
    J Clin Pharmacol; 2017 Jun; 57(6):796-804. PubMed ID: 28052338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Azithromycin on Venetoclax Pharmacokinetics in Healthy Volunteers: Implications for Dosing Venetoclax with P-gp Inhibitors.
    Agarwal SK; Tong B; Bueno OF; Menon RM; Salem AH
    Adv Ther; 2018 Nov; 35(11):2015-2023. PubMed ID: 30264382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma.
    Agarwal SK; Salem AH; Danilov AV; Hu B; Puvvada S; Gutierrez M; Chien D; Lewis LD; Wong SL
    Br J Clin Pharmacol; 2017 Apr; 83(4):846-854. PubMed ID: 27859472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical evaluation of P-glycoprotein inhibition by venetoclax: a drug interaction study with digoxin.
    Chiney MS; Menon RM; Bueno OF; Tong B; Salem AH
    Xenobiotica; 2018 Sep; 48(9):904-910. PubMed ID: 29027832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of Venetoclax-Posaconazole Interaction in Acute Myeloid Leukemia Patients: Evaluation of Dose Adjustments.
    Agarwal SK; DiNardo CD; Potluri J; Dunbar M; Kantarjian HM; Humerickhouse RA; Wong SL; Menon RM; Konopleva MY; Salem AH
    Clin Ther; 2017 Feb; 39(2):359-367. PubMed ID: 28161120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Rifampin on the Pharmacokinetics of Ertugliflozin in Healthy Subjects.
    Dawra VK; Sahasrabudhe V; Liang Y; Matschke K; Shi H; Hickman A; Saur D; Terra SG; Cutler DL
    Clin Ther; 2018 Sep; 40(9):1538-1547. PubMed ID: 30170758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma.
    Salem AH; Agarwal SK; Dunbar M; Enschede SL; Humerickhouse RA; Wong SL
    J Clin Pharmacol; 2017 Apr; 57(4):484-492. PubMed ID: 27558232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Semimechanistic Modeling to Guide Venetoclax Coadministration with Ritonavir and Digoxin.
    Alhadab AA; Salem AH; Freise KJ
    Clin Transl Sci; 2020 May; 13(3):555-562. PubMed ID: 31961475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of rifampin on the pharmacokinetics, safety and tolerability of navitoclax (ABT-263), a dual inhibitor of Bcl-2 and Bcl-XL , in patients with cancer.
    Yang J; Pradhan RS; Rosen LS; Graham AM; Holen KD; Xiong H
    J Clin Pharm Ther; 2014 Dec; 39(6):680-4. PubMed ID: 25047139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Low- and High-Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First-in-Class BCL-2 Inhibitor.
    Salem AH; Agarwal SK; Dunbar M; Nuthalapati S; Chien D; Freise KJ; Wong SL
    J Clin Pharmacol; 2016 Nov; 56(11):1355-1361. PubMed ID: 27029823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patients: a Pooled Population Pharmacokinetic Analysis.
    Jones AK; Freise KJ; Agarwal SK; Humerickhouse RA; Wong SL; Salem AH
    AAPS J; 2016 Sep; 18(5):1192-1202. PubMed ID: 27233802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effect of Single and Multiple Doses of Rifampin on the Pharmacokinetics of Doravirine in Healthy Subjects.
    Yee KL; Khalilieh SG; Sanchez RI; Liu R; Anderson MS; Manthos H; Judge T; Brejda J; Butterton JR
    Clin Drug Investig; 2017 Jul; 37(7):659-667. PubMed ID: 28353169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of the B-Cell Lymphoma 2 (Bcl-2) Inhibitor Venetoclax in Female Subjects with Systemic Lupus Erythematosus.
    Minocha M; Zeng J; Medema JK; Othman AA
    Clin Pharmacokinet; 2018 Sep; 57(9):1185-1198. PubMed ID: 29333561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coadministration of Rifampin Significantly Reduces Odanacatib Concentrations in Healthy Subjects.
    Stoch SA; Ballard J; Gibson C; Kesisoglou F; Witter R; Kassahun K; Zajic S; Mehta A; Brandquist C; Dempsey C; Stypinski D; Reitman ML
    J Clin Pharmacol; 2017 Jan; 57(1):110-117. PubMed ID: 27321774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Subjects with Hepatic Impairment.
    Salem AH; Dave N; Marbury T; Hu B; Miles D; Agarwal SK; Bueno OF; Menon RM
    Clin Pharmacokinet; 2019 Aug; 58(8):1091-1100. PubMed ID: 30949874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the effect of multiple doses of rifampin on the pharmacokinetics and safety of ponatinib in healthy subjects.
    Narasimhan NI; Dorer DJ; Davis J; Turner CD; Sonnichsen D
    Clin Pharmacol Drug Dev; 2015 Sep; 4(5):354-60. PubMed ID: 27137144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exposure-Response Analyses of the Effects of Venetoclax, a Selective BCL-2 Inhibitor, on B-Lymphocyte and Total Lymphocyte Counts in Women with Systemic Lupus Erythematosus.
    Nader A; Minocha M; Othman AA
    Clin Pharmacokinet; 2020 Mar; 59(3):335-347. PubMed ID: 31541431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib.
    Mohamed MF; Jungerwirth S; Asatryan A; Jiang P; Othman AA
    Br J Clin Pharmacol; 2017 Oct; 83(10):2242-2248. PubMed ID: 28503781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.